lunes, 28 de noviembre de 2016

Efficacy and safety of re-treatment with the same artemisinin-based combination treatment (ACT) compared with an alternative ACT and quinine plus clindamycin after failure of first-line recommended ACT (QUINACT): a bicentre, open-label, phase 3, randomised controlled trial

Efficacy and safety of re-treatment with the same artemisinin-based combination treatment (ACT) compared with an alternative ACT and quinine plus clindamycin after failure of first-line recommended ACT (QUINACT): a bicentre, open-label, phase 3, randomised controlled trial: Re-treatment with the same ACT shows similar efficacy as recommended rescue treatments
and could be considered for rescue treatment for Plasmodium falciparum malaria. However,
the effect of this approach on the selection of resistant strains should be monitored
to ensure that re-treatment with the same ACT does not contribute to P falciparum
resistance.

No hay comentarios:

Publicar un comentario